J. McEvoy

417 total citations
15 papers, 328 citations indexed

About

J. McEvoy is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, J. McEvoy has authored 15 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 4 papers in Pediatrics, Perinatology and Child Health and 3 papers in Pharmacology. Recurrent topics in J. McEvoy's work include Schizophrenia research and treatment (11 papers), Electroconvulsive Therapy Studies (4 papers) and Bipolar Disorder and Treatment (3 papers). J. McEvoy is often cited by papers focused on Schizophrenia research and treatment (11 papers), Electroconvulsive Therapy Studies (4 papers) and Bipolar Disorder and Treatment (3 papers). J. McEvoy collaborates with scholars based in United States, Netherlands and Czechia. J. McEvoy's co-authors include Gregory S. Kolt, Diana O. Perkins, Robert M. Hamer, G.D. Tollefson, Mauricio Tohen, Jeffrey A. Lieberman, Paul M. Thompson, Michael Yu, C. Charles and Kôji Hayashi and has published in prestigious journals such as American Journal of Psychiatry, Cerebral Cortex and Schizophrenia Research.

In The Last Decade

J. McEvoy

15 papers receiving 312 citations

Peers

J. McEvoy

PMH

PHARM

RNMI

PHYSI

Débora Pastore Bassitt Brazil

Kenta Wakaizumi Japan

Lian Beijers Netherlands

Samuel M. Bierner United States

Pär Flodin Sweden

Emmanuelle Opsommer Switzerland

David Busenbark United States

Juliana Ferreira Sauer Brazil

Sergio Moreno Spain

Liduïn E. M. Souren United States

Débora Pastore Bassitt Brazil

J. McEvoy

231 ×1.5

PMH

48 ×0.4

PHARM

141 ×2.2

78 ×1.7

RNMI

26 ×0.7

PHYSI

Citations per year, relative to J. McEvoy J. McEvoy (= 1×) peers Débora Pastore Bassitt

Countries citing papers authored by J. McEvoy

Since Specialization

Citations

This map shows the geographic impact of J. McEvoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. McEvoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. McEvoy more than expected).

Fields of papers citing papers by J. McEvoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. McEvoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. McEvoy. The network helps show where J. McEvoy may publish in the future.

Co-authorship network of co-authors of J. McEvoy

This figure shows the co-authorship network connecting the top 25 collaborators of J. McEvoy. A scholar is included among the top collaborators of J. McEvoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. McEvoy. J. McEvoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Shim, Vickie, et al.. (2024). Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System. Annals of Surgical Oncology. 32(1). 75–83. 2 indexed citations

McEvoy, J., Leslie Citrome, Jay Hsu, et al.. (2013). 1046 – Switching To Lurasidone In Patients With Schizophrenia: Tolerability And Effectiveness At 6 Weeks And 6 Months. European Psychiatry. 28(S1). 2 indexed citations

Lieberman, Jeffrey A., G.D. Tollefson, A. I. Green, et al.. (2009). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)). American Journal of Psychiatry. 166(8). 12 indexed citations

Thompson, Paul M., George Bartzokis, Kôji Hayashi, et al.. (2008). Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments. Cerebral Cortex. 19(5). 1107–1123. 83 indexed citations

Kolt, Gregory S. & J. McEvoy. (2003). Adherence to rehabilitation in patients with low back pain. Manual Therapy. 8(2). 110–116. 135 indexed citations

Brown, Duncan, et al.. (2003). Aripiprazole in patients with first episode schizophrenia. Schizophrenia Research. 60(1). 275–275. 3 indexed citations

Perkins, Diana O., J.A. Lieberman, Hongbin Gu, et al.. (2003). Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders. Schizophrenia Research. 60(1). 24–24. 5 indexed citations

Gu, Hongbin, Ira Glick, Diana O. Perkins, et al.. (2003). Clinical correlates of weight gain in first episode psychosis patients treated with olanzapine. Schizophrenia Research. 60(1). 372–372. 6 indexed citations

Lieberman, J.A., H. Cecil Charles, T. Sharma, et al.. (2003). Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. Schizophrenia Research. 60(1). 293–293. 11 indexed citations

10.

McEvoy, J., J.A. Lieberman, Diana O. Perkins, et al.. (2003). Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia. Schizophrenia Research. 60(1). 313–313. 24 indexed citations

11.

Bilder, Robert M., R.S. Goldman, Jan Volavka, et al.. (2001). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder. European Neuropsychopharmacology. 11. S256–S256. 16 indexed citations

12.

Mohr, Pavel, Jan Volavka, J.A. Lieberman, et al.. (2000). FC09.05 Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia. European Psychiatry. 15(S2). 284s–284s. 6 indexed citations

13.

McEvoy, J., H.Y. Meltzer, M. Hammer, et al.. (1993). The efficacy and tolerability of sertindole in schizophrenic patients: A pilot, double-blind, placebo-controlled, dose-ringing study. Schizophrenia Research. 9(2-3). 244–244. 13 indexed citations

14.

McEvoy, J., et al.. (1982). Bromperidol Maintenance in Schizophrenia*. Pharmacopsychiatry. 15(3). 95–96. 1 indexed citations

15.

McEvoy, J., et al.. (1981). A Double-blind Comparison of Bromperidol and Haloperidol in Newly Admitted Schizophrenic Patients. Pharmacopsychiatry. 14(4). 139–140. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact